Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen by Michael L. McCaleb, Steven G. Hughes, Tamar R. Grossman, Ashley Frazer-Abel, Bill Jung, Lixuan Yin, Scott P. Henry, Brett P. Monia, Eugene Schneider, Richard Geary, Gary T. Brice

Get full text